From that perspective, enantiomer (+)-4 R, with its higher specificity for the α12βγδ nAChR compared with the α7 and α4β2 subtypes, and its tighter binding to key residue Trp147 in the A-AChBP binding pocket compared with enantiomer (−)-4 S, appears as a suitable starting point in a context of muscle-linked diseases. This evidence concerns the gene CHRNA4 and glycogen storage disease VI.